One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration

Cheryl A. Arcinue, Feiyan Ma, Giulio Barteselli, Lucie Sharpsten, Maria Laura Gomez, William R. Freeman

Research output: Contribution to journalArticle

Abstract

Purpose To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. Results Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P

Original languageEnglish
Pages (from-to)426-436
Number of pages11
JournalAmerican Journal of Ophthalmology
Volume159
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Recurrence
Injections
aflibercept

ASJC Scopus subject areas

  • Ophthalmology

Cite this

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. / Arcinue, Cheryl A.; Ma, Feiyan; Barteselli, Giulio; Sharpsten, Lucie; Gomez, Maria Laura; Freeman, William R.

In: American Journal of Ophthalmology, Vol. 159, No. 3, 01.03.2015, p. 426-436.

Research output: Contribution to journalArticle

Arcinue, Cheryl A. ; Ma, Feiyan ; Barteselli, Giulio ; Sharpsten, Lucie ; Gomez, Maria Laura ; Freeman, William R. / One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. In: American Journal of Ophthalmology. 2015 ; Vol. 159, No. 3. pp. 426-436.
@article{b0aeae81b3994a2caa29418e246fe2cf,
title = "One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration",
abstract = "Purpose To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. Results Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3{\%} of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P",
author = "Arcinue, {Cheryl A.} and Feiyan Ma and Giulio Barteselli and Lucie Sharpsten and Gomez, {Maria Laura} and Freeman, {William R.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ajo.2014.11.022",
language = "English",
volume = "159",
pages = "426--436",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration

AU - Arcinue, Cheryl A.

AU - Ma, Feiyan

AU - Barteselli, Giulio

AU - Sharpsten, Lucie

AU - Gomez, Maria Laura

AU - Freeman, William R.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. Results Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P

AB - Purpose To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. Results Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P

UR - http://www.scopus.com/inward/record.url?scp=84922675324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922675324&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2014.11.022

DO - 10.1016/j.ajo.2014.11.022

M3 - Article

C2 - 25461263

AN - SCOPUS:84922675324

VL - 159

SP - 426

EP - 436

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -